Nisa Investment Advisors
CPRX icon

Nisa Investment Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

Nisa Investment Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$133K Buy
5,381
+51
+1% +$1.22K ﹤0.01% 1333
2025
Q4 		$124K Sell
5,330
-120
-2% -$2.67K ﹤0.01% 1362
2025
Q3 		$107K Sell
5,450
-58
-1% -$1.19K ﹤0.01% 1412
2025
Q2 		$120K Buy
5,508
+15
+0.3% +$354 ﹤0.01% 1344
2025
Q1 		$133K Sell
5,493
-41
-0.7% -$923 ﹤0.01% 1328
2024
Q4 		$115K Buy
5,534
+243
+5% +$5.22K ﹤0.01% 1439
2024
Q3 		$105K Buy
5,291
+11
+0.2% +$204 ﹤0.01% 1433
2024
Q2 		$81.8K Buy
5,280
+109
+2% +$1.7K ﹤0.01% 1523
2024
Q1 		$82.4K Buy
5,171
+92
+2% +$1.39K ﹤0.01% 1526
2023
Q4 		$85.4K Buy
5,079
+3,829
+306% +$52.3K ﹤0.01% 1479
2023
Q3 		$14.6K Hold
1,250
– – ﹤0.01% 2099
2023
Q2 		$16.8K Sell
1,250
-1,570
-56% -$22.6K ﹤0.01% 2147
2023
Q1 		$47K Buy
2,820
+1,550
+122% +$25.6K ﹤0.01% 1733
2022
Q4 		$24K Sell
1,270
-700
-36% -$10.8K ﹤0.01% 2007
2022
Q3 		$27K Sell
1,970
-350
-15% -$4.15K ﹤0.01% 1962
2022
Q2 		$16K Buy
+2,320
New +$17K ﹤0.01% 2096

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Nisa Investment Advisors's CPRX Position: Q1 2026 in Review

Nisa Investment Advisors increased its Catalyst Pharmaceutical (CPRX) stake by 0.96% in Q1 2026, buying an estimated $1.22K and bringing the position to 5,381 shares worth $133K. The position accounts for ﹤0.01% of the portfolio, ranked #1333.

Nisa Investment Advisors first reported a position in CPRX in Q2 2022 and has held it in 16 quarters since. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Nisa Investment Advisors held 5,381 shares of Catalyst Pharmaceutical worth $133K as of Q1 2026.
  • Nisa Investment Advisors bought 51 Catalyst Pharmaceutical shares in Q1 2026, an estimated $1.22K.
  • Catalyst Pharmaceutical made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q1 2026, its #1333 holding.
  • Nisa Investment Advisors first reported a position in Catalyst Pharmaceutical in Q2 2022 and has held it in 16 quarters since.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Nisa Investment Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.